diagnost tool
unexpect market dynam trip
big pictur still intact buy pt
acknowledg declin share fair given miss top-lin
guid expect pl deal get done soon help
reduct headwind associ test denial easier comp weather
expans retail big pictur intact take share
higher cost less effici lab hospit pois win busi
lh share larg contract expect acceler pace
reiter buy trim pt adj ep
adj ep came penni short our/street rev
miss came street revenue /req
neg surpris vs street
challeng volum grew mainli due
higher commerci payor denial prescript drug monitor vitamin
test declin hcv genotyp test see page detail organ
volum saw lower expect growth
due polici chang propos payer limit mostli unnecessari
confirmatori test lobbi payer chang polici
revers one payor decis hcv test declin due rapid uptak
new mavyret drug genotyp lower demand hepat
genotyp hcvg test could neg read-through buy-rat
aet contract proactiv reach physician unit
network use lh in-network lab alreadi win new
custom case busi could shift out-of-network jan
believ number account use anoth lab
in-network big opportun take share estim
add rev first two year year
assum time lab could captur half larg contract base
estim could bolt net rev lh time expect volum
shift unh/aet take time play beyond
guide/model lower revenue guid y/i
midpoint y/i midpoint tighten
adj ep guid maintain adj ep
nudg rev low end guid maintain
revenue growth target respect year estim
includ acquisit typic accret
acla vs lawsuit indic side submit brief
court await judg rule brief set date hear oral argument
think posit chang lawsuit move share lh higher
 recal complet acquisit ad point revenue
growth contribut basi point revenue growth
reiter guid add point revenu growth
price close busi juli
largest clinic lab us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
unexpect market dynam trip
big pictur intact buy pt
acknowledg weak share today fair given unexpect
miss adj ep specif revenu result top-lin
guid expect factor acceler rate growth
pl deal w/ hospit announc soon help
reduct headwind test denial easier comp weather
recal last year hurrican pull volum
expans retail big pictur intact take share higher
cost less effici lab hospit pois win busi lh
share larg contract expect acceler pace
reiter buy trim pt adj ep
adj ep came penni short our/street rev
miss came street revenue /req
neg surpris vs street
volum pressur volum grew mainli due
higher commerci payor denial prescript drug monitor vitamin
test declin hcv genotyp test organ volum
saw lower expect growth due polici chang
propos payer limit mostli unnecessari confirmatori test
lobbi payer chang polici revers one payor decis
hcv test declin due rapid uptak new mavyret drug
genotyp lower demand hepat genotyp hcvg test
could neg read-through buy-rat view share
today thu pressur may alreadi bake
stock weak today though acknowledg risk gnmk revenu
guidanc pressur directli impact
call new paradigm shift hcv test see pressur
hepat genotyp test could neg impact
quest call faster expect declin genotyp resist test
hcv neg factor attribut declin rapid accept
abbvi mavyret hcv drug gener revenu
track year ahead abbv initi expect mavyret
pose problem long-tim market leader hcv test
report total hep revenu harvoni sovaldi epclusa vosevi
billion y/i due higher competit lower price drug
report total hep revenu y/i
come mavyret approv august major
hcv genotyp abbv treatment regimen achiev cure rate
littl week price regimen
compar price gild sovaldi regimen
gild regimen harvoni
indic call alreadi achiev market share us
market sinc august fda approv given dramat shift hep-c market
share result mavyret requir follow-up genotyp quest
manag indic expect hcv volum grow go forward
research suggest american genotyp
fewer american frankli surpris hear
commentari immedi impact mavyret
buy unchang target price juli
diagnost tool
prescript drug monitor still grow nice rate denial rose
indic prescript drug monitor growth strong less
expect due polici chang payor aim toward limit test quest
engag directli payer lobbi medic necess
test quest success get least one payer revers polici chang
well road discuss addit payer quest indic
us polici chang result bad actor lab bill
june opportun tour dgx state-of-the-art lab
futur massachusett quest indic drive y/i volum
growth prescript drug monitor pain manag doc
prescrib drug enabl individu deal pain relat chronic condit
use arsen mass spec instrument thermo assist
monitor patient complianc determin whether patient take drug
sell illeg someon els indic much
aet contract remind access network
in-network basi begin januari remind alreadi serv
busi out-of-network basi quantifi size
indic call proactiv reach doc network
use lh in-network lab alreadi win new custom
case busi could shift out-of-network jan believ
number account use anoth lab
in-network big opportun take share estim
add rev first two year year
assum time lab could captur half larg contract base
estim could bolt net rev lh time expect
volum shift unh/aet take time play beyond
guide/model lower revenue guid y/i
midpoint y/i midpoint tighten
adj ep guid maintain adj ep
nudg rev low end guid maintain
revenue growth target respect model
adj ep respect exclud acquisit
announc typic accret
what bake guidanc
dgx slightli lower revenu guid contempl follow
hcv genotyp resist test expect return growth
prescript drug monitoring- plan place revers number
polici chang serv off-set denial seen
vitamin testing- believ misunderstand around
appropri code vitamin test expect mitig
throughout back half
profession lab servic pl agreements- expect close
agreement yet announc would surpris see
announc pl agreement within next month two
last year hurrican make easier comp
impact felt carryov well note
guarante lighter hurrican season year case
may troubl meet guid
buy unchang target price juli
diagnost tool
expect growth acceler throughout
pama continu await updat acla lawsuit
indic side submit brief court await judg
rule brief set date hear oral argument think chang
statu quo lawsuit might propel lh stock higher market
could assign higher multipl draconian reimburs cut
view overhang stock
oper insid locat florida texa
locat end approach safeway locat
indic conduct pilot number retail includ
consid huge opportun dgx myquest mobil applic
user host ndr march indic myquest mobil
app user increas y/i roughli user plan provid
extens updat consum initi includ myquest digit experi
consum offer investor day novemb
 indic call hospit pipelin remain strong
recal complet acquisit ad point revenue growth
 contribut basi point revenue growth
reiter guid add point revenu growth
compani coverag mention report
laboratori corpor america hold lh nyse buy
buy unchang target price juli
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price juli
diagnost tool
canaccord genuiti estim compani report
buy unchang target price juli
diagnost tool
